Recursion Pharmaceuticals Raises $60M
Salt Lake City-based Recursion Pharmaceuticals has raised $60 in a Series B funding, the company said this morning, in a round led by Data Collective. The round also included Lux Capital, Obvious Ventures, Advantage Capital, Felicis, Epic, AME plus new investor Mubadala, Menlo Ventures, CRV, Two Sigma, along with angels. Recursion Pharmaceuticals is combining biological sciences with artificial intelligence software for the drug discovery market. Chris Gibson is Co-Founder and CEO of Recursion. As part of the funding, Zachary Bogue, Managing Partner of Data Collective (DCVC), will join the company's board.
posted on Tuesday, October 3, 2017
Related companies:
Recursion Pharmaceuticals, LLC
Related stories:
> Recursion Pharmaceuticals Names COO
> Recursion Ups Series A To $15.05M
> Recursion Pharmaceuticals Adds Scientific Advisor
> Recursion Pharmaceuticals Gets $12.9M To Apply AI To Drug Discovery
> Prolexys Pharmaceuticals Raises $20M
Techrockies.com Home